Metacrine
IPONuclear receptor therapies for liver and metabolic disease
Public · San Diego, United States · Founded 2015 · $123.0M raised
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- metacrine.com
- Total Funding
- $123.0M
- Last Round
- $65.0M Series CJun 2018
- Rounds
- 3
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 4 funding rounds and 8 investors for this company. The full record is or through the API.
About
Metacrine is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver, gastrointestinal, and metabolic diseases. The company targets nuclear receptors involved in disease pathways, with a pipeline aimed at conditions such as NASH and inflammatory bowel disease.
Summary
Metacrine is a Biotech company based in San Diego, United States, founded in 2015. It has raised $123.0M in total across 3 rounds, most recently a $65.0M Series C round in Jun 2018. Investors include Alexandria Venture Investments, ARCH Venture Partners and Polaris Partners.
Funding & Exit History
Sep 2020
Sign up to see all 4 events
Funding: Series A through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/metacrine"><img src="https://indexed.vc/api/badge/company/metacrine" alt="Metacrine on Indexed.vc" width="260" height="76" /></a>